Slow recovery of human brain MAO B after L-Deprenyl (Selegeline) withdrawal
作者： Jean Logan , Gene-Jack Wang , Robert R. Mac Gregor , David Schlyer , Alfred P. Wolf
关键词:
摘要: L-Deprenyl (Selegeline) is an enzyme-activated irreversible inhibitor of monoamine oxidase B (MAO B; EC 1.4.3.4). It used to treat Parkinson's disease at a dose 5 mg twice day. Since enzyme inhibition irreversible, the recovery functional activity after withdrawal from L-deprenyl requires synthesis new enzyme. We have measured 40 day half-time for brain MAO in and normal subjects L-deprenyl. This first measurement rate specific protein living human brain. currently by 50,000 patients with United States its use expected increase reports that it may be beneficial Alzheimer's disease. The slow turnover suggests current clinical excessive efficacy reduced dosing should evaluated. Such evaluation mechanistic importance as well impact on reducing side effects costs arising drug use. © 1994 Wiley-Liss, Inc.1
sci-hub.se 参考文章(45)
KS Ansari, PH Yu, TP Kruck, WG Tatton, Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition The Journal of Neuroscience. ,vol. 13, pp. 4042- 4053 ,(1993) , 10.1523/JNEUROSCI.13-09-04042.1993
M.-C. Carrillo, K. Kitani, S. Kanai, Y. Sato, G.O. Ivy, The ability of (-)deprenyl to increase superoxide dismutase activities in the rat is tissue and brain region selective. Life Sciences. ,vol. 50, pp. 1985- 1992 ,(1992) , 10.1016/0024-3205(92)90528-W
, Karl Kieburtz, A controlled trial of lazabemide (RO19–6327) in untreated Parkinson's disease Annals of Neurology. ,vol. 33, pp. 350- 356 ,(1993) , 10.1002/ANA.410330404
Chie Okuda, David S. Segal, Ronald Kuczenski, Deprenyl alters behavior and caudate dopamine through an amphetamine-like action. Pharmacology, Biochemistry and Behavior. ,vol. 43, pp. 1075- 1080 ,(1992) , 10.1016/0091-3057(92)90484-W
Ruey-Meei Wu, Chuang C. Chiueh, Agu Pert, Dennis L. Murphy, Apparent antioxidant effect of l-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo European Journal of Pharmacology. ,vol. 243, pp. 241- 247 ,(1993) , 10.1016/0014-2999(93)90181-G
John H. Growdon, Treatment for Alzheimer's Disease? The New England Journal of Medicine. ,vol. 327, pp. 1306- 1308 ,(1992) , 10.1056/NEJM199210293271810
C. Goridis, N. H. Neff, Monoamine oxidase: an approximation of turnover rates. Journal of Neurochemistry. ,vol. 18, pp. 1673- 1682 ,(1971) , 10.1111/J.1471-4159.1971.TB03740.X
Margherita Strolin Benedetti, Philippe Dostert, Monoamine oxidase, brain ageing and degenerative diseases. Biochemical Pharmacology. ,vol. 38, pp. 555- 561 ,(1989) , 10.1016/0006-2952(89)90198-6
J. Tetrud, J. Langston, The effect of deprenyl (selegiline) on the natural history of Parkinson's disease Science. ,vol. 245, pp. 519- 522 ,(1989) , 10.1126/SCIENCE.2502843
K. Kitani, S. Kanai, Y. Sato, M. Ohta, G.O. Ivy, M-C. Carrillo, Chronic treatment of (-)deprenyl prolongs the life span of male fischer 344 rats. Further evidence Life Sciences. ,vol. 52, pp. 281- 288 ,(1993) , 10.1016/0024-3205(93)90219-S